Edition:
United States

Sun Pharmaceutical Industries Ltd (SUN.BO)

SUN.BO on Bombay Stock Exchange

568.55INR
26 May 2017
Change (% chg)

Rs-23.25 (-3.93%)
Prev Close
Rs591.80
Open
Rs592.00
Day's High
Rs598.45
Day's Low
Rs564.90
Volume
1,248,995
Avg. Vol
365,523
52-wk High
Rs854.50
52-wk Low
Rs564.90

SUN.BO

Chart for SUN.BO

About

Sun Pharmaceutical Industries Limited is a pharmaceuticals company. The Company's business segments include US Business, Indian Branded Generics Business, Emerging Markets, Global Consumer Healthcare Business and Active Pharmaceutical Ingredients (API). Its Rest of World segment includes Western Europe, Canada, Australia, New... (more)

Overall

Beta: 0.22
Market Cap(Mil.): Rs1,361,966.00
Shares Outstanding(Mil.): 2,399.31
Dividend: 1.00
Yield (%): 0.18

Financials

  SUN.BO Industry Sector
P/E (TTM): 18.38 14.27 17.41
EPS (TTM): 30.89 -- --
ROI: -- -7.17 -5.42
ROE: -- -6.63 -4.68

UPDATE 1-India's Sun Pharma says 2018 sales may fall as U.S. market gets tougher

* Q4 U.S. sales slide 34 pct (Adds Managing Director comments from conference call)

May 26 2017

BRIEF-India's Sun Pharma says expects to launch psoriasis drug next year

* MD Dilip Shanghvi says needs to execute U.S. business better

May 26 2017

BRIEF-Sun Pharma may have single digit decline in consol revenue for FY 18 vs FY 17 - exec

* Dilip Shanghvi says may have single digit decline in consol revenue for FY 18 versus FY 17

May 26 2017

India's Sun Pharma fourth-quarter profit down 13.6 pct

MUMBAI, May 26 Sun Pharmaceutical Industries Ltd , India's largest drugmaker by sales, reported a 13.6 percent drop in its fourth-quarter profit due to slow sales in the United States.

May 26 2017

BRIEF-India's Sun Pharmaceutical Industries March-qtr consol profit down about 14 pct

* Consensus forecast for March quarter consol profit was 14.95 billion rupees

May 26 2017

BRIEF-Sun Pharma announces fda filing acceptance of Biologics License Application for tildrakizumab

* Sun Pharma announces U.S. FDA filing acceptance of Biologics License Application (bla) for tildrakizumab Source text for Eikon: Further company coverage:

May 24 2017

BRIEF-Sun Pharma says US FDA files acceptance of BLA for Tildrakizumab

* Says US FDA filing acceptance of biologics license application (BLA) for Tildrakizumab

May 24 2017

BRIEF-Sun Pharma says filing of tildrakizumab with European Medicines Agency by Almirall

* Says validation of regulatory filing of tildrakizumab with the european medicines agency (EMA) by Almirall.

Mar 24 2017

BRIEF-Sun Pharma Industries says Canadian unit to acquire Thallion Pharma

* Taro Pharmaceuticals Inc. (Canada) entered into deal to acquire all issued and outstanding shares of Thallion Pharma

Mar 17 2017

India's Sun Pharma says U.S. FDA to lift ban on Mohali plant exports

MUMBAI India's largest drugmaker Sun Pharmaceutical Industries said U.S. regulators plan to lift a ban on its Mohali plant in northern India, paving the way for a resumption of exports to the company's biggest market after four years.

Mar 14 2017

More From Around the Web

Earnings vs. Estimates